HCP 02
Medical Oncologist · France · Department head
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Weighs quality-of-life and tolerability heavily; supportive but wants durability data before changing practice.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
5 improved
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“This is a setting where we badly need options, and this endpoint really moves the needle for me.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“I would prescribe it, provided we have a realistic monitoring pathway in place.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“The absolute benefit in this group is enough to justify the exposure for me.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“It depends on the interval — a late recurrence is a very different conversation from an early one.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“The effect relative to the comparators is enough to make this my first choice.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“It is acceptable, as long as routine monitoring is feasible in the clinic.”